Differentially expressed genes involved in these pathways such as Pik3r1, Foxo1, Foxo3, Scd1, Col3a1 and Fn1 might be candidate targets for NAFLD therapy. This evidence concerns the gene COL3A1 and metabolic dysfunction-associated steatotic liver disease.